期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

二肽基肽酶-4抑制剂在2型糖尿病治疗中的研究进展 被引量：7

原文传递
导出
摘要 世界卫生组织对糖尿病流行病学调查显示到2030年仅中国将有2型糖尿病患者1．297亿，所以2型糖尿病的长期预防和治疗极其重要。2型糖尿病是一种极其复杂的内分泌和代谢紊乱疾病，
作者 戈慧颖 丛丽
机构地区 哈尔滨医科大学附属第二医院内分泌科哈尔滨医科大学激素与内分泌疾病重点实验室
出处 《中国医师进修杂志》 2013年第31期73-75,共3页 Chinese Journal of Postgraduates of Medicine
关键词 2型糖尿病 二肽基肽酶 治疗 抑制剂 流行病学调查 世界卫生组织 代谢紊乱 内分泌
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献17

  • 1Engel M,Hoffmann T,Wagner L,et al.The crystal structure of dipeptidyl peptidase Ⅳ (CD26) reveals its functional regulation and enzymatic mechanism.Proc Natl Acad Sci U S A,2003,100(9):5063-5068.
  • 2Ferreira L,Teixeira-de-Lemos E,Pinto F,et al.Effects of sitagliptin treatment on dysmetabolism,inflammation,and oxidative stress in an animal model of type 2 diabetes (ZDF Rat).Mediators Inflamm,2010:592760.
  • 3Vahl TP,Tauchi M,Durler TS,et al.Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.Endocrinology,2007,148(10):4965-4973.
  • 4Raz I,Hanefeld M,Xu L,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.Diabetologia,2006,49 (11):2564-2571.
  • 5Rhee E,Lee WY,Min KW,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.Diabetes Obes Metab,2013,15(6):523-530.
  • 6Mistry GC,Maes AL,Lasseter KC,et al.Effect of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on blood pressure in nondiabetic patients with mild to moderate hypertension.J Clin Pharmacol,2008,48 (5):592-598.
  • 7Bergman A,Ebel D,Liu F,et al.Absolute bioavailability of sitagliptin,an oral dipeptidyl peptidase-4 inhibitor,in healthy volunteers.Biopharm Drug Dispos,2007,28 (6):315-322.
  • 8Nauck MA,Meininger G,Sheng D,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,sitagliptin,compared with the sulfhonylurea,glipizide,in patients with type 2 diabetes inadequately controlled on metformin alone:a randomized double-blind,non-inferiority trial.Diabetes Obes Metab,2007,9(2):194-205.
  • 9Lenski M,Kazakov A,Marx N,et al.Effects of DPP-4 inhibition on cardiac metabolism and function in mice.J Mol Cell Cardiol,2011,51(6):906-918.
  • 10Ahrén B,Pacini G,Tura A,et al.Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.Horm Metab Res,2007,39(11):826-829.

同被引文献50

  • 1Vandana Saini.Molecular mechanisms of insulin resistance in type 2 diabetes mellitus[J].World Journal of Diabetes,2010,1(3):68-75. 被引量：24
  • 2Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Ensl J Med, 2010,362 (12) : 1090-1101.
  • 3Adamopoulos S, Parissis J, Kroupis C, et al. Physical training re- duces peripheral markers of inflammation in patients with chronic heart failureI-J']. Eur Heart J, 2001, 22(9)5 791-797.
  • 4Pacini G, Tufa A. Improved meal--related insulin processing con- tributes to the enhancement of B--cell function by the DPP--4 in- hibitor vi|dagllptin in patients type 2 diabetes[J]. Horm MetabRes, 2007,39(11) :826-829.
  • 5Raz I, Hanefeld M,Xu L, et a l. Efficacy and safety of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus['J]. Diabetologia, 2006,49 ( 11 ) : 2564-2571.
  • 6Nauck MA,Meininger G,Sheng D,et al. Efficacy and safety of the dipeptidyl peptidase-- 4 inhibitor, sitagliptin,compared with the sull- honylurea, glipizide, in patients with type 2 diabetes inadequately controlled on mefformin alone:a randomized double-blind, non--in- feriority trial[J]. Diabetes Obes Metab, 2007,9 (2) : 194-205.
  • 7Lenski M, Kazal A, Marx N,et al. Effects of DPP-- 4 inhibition on cardiac metabohsm and function in mice[J]. J Mol Cell Cardiol, 2011,51 (6) z 906-918.
  • 8Charles MA,Eschwege E.Prevention of type 2 diabetes:role of metformin[J].Drugs,1999,58 Suppl 1:S71-73.
  • 9Asmar M,Holst JJ.Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide:new advances[J].Curr Opin Endocrinol Diabetes Obes,2010,17(1):57-62.
  • 10柴杰,阎德文,李海燕,李明政,黄少华.不同方式胰岛素强化治疗对初诊2型糖尿病患者胰岛β细胞功能的影响[J].临床内科杂志,2012,29(8):553-556. 被引量：10

引证文献7

二级引证文献18

中国医师进修杂志
2013年 第31期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部